Nav: Home

Sugar sponges sop up and release glucose as needed

May 31, 2017

Many diabetes patients must inject themselves with insulin, sometimes several times a day, while others take medications orally to control blood sugar. The injections, as well as the side effects from both regimens, can be painful. Now, one team reports in the Journal of the American Chemical Society progress toward an insulin-free diabetes treatment that requires fewer injections.

According to the U.S. Centers for Disease Control and Prevention, current trends predict that one in three adults in the U.S. will have diabetes by 2050. Treatments include insulin injections, which can be painful. In addition, the injections can involve different types of insulin -- a slow-acting one before bed or a fast-acting one before meals -- which can be confusing. Pills are not much better, as patients sometimes forget to take them. Both drugs and injections can have various side effects, including nerve damage, infections and insulin resistance. Non-invasive insulin-dependent systems that include hydrogels and polymers have developed in the laboratory, but they also can trigger these complications. So Jianzhong Du and colleagues wanted to develop a method that would be easy to use and that would avoid side effects.

The researchers nicknamed their treatment the "sugar sponge." It's an injected lectin-coated polymer vesicle that sopped up and bound glucose when glucose levels were high, and released the sugar when its concentrations were low in laboratory tests. They also tested the sponge in mice with type-I diabetes, and within two days, they saw antidiabetic effects. The researchers say that the sponge could one day serve as a treatment for either type-I or type-II diabetes.
-end-
The authors acknowledge funding from the National Natural Science Foundation of China, Shanghai International Scientific Collaboration Fund, Thousand Talents Plan (China) and the Fundamental Research Fund for the Central Universities.

The abstract that accompanies this study is available here.

The American Chemical Society, the world's largest scientific society, is a not-for-profit organization chartered by the U.S. Congress. ACS is a global leader in providing access to chemistry-related information and research through its multiple databases, peer-reviewed journals and scientific conferences. ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies. Its main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive news releases from the American Chemical Society, contact newsroom@acs.org.

Follow us on Twitter | Facebook

American Chemical Society

Related Diabetes Articles:

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).
Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.
People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.
Diabetes, but not diabetes drug, linked to poor pregnancy outcomes
New research indicates that pregnant women with pre-gestational diabetes who take metformin are at a higher risk for adverse pregnancy outcomes -- such as major birth defects and pregnancy loss -- than the general population, but their increased risk is not due to metformin but diabetes.
New oral diabetes drug shows promise in phase 3 trial for patients with type 1 diabetes
A University of Colorado Anschutz Medical Campus study finds sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes.
More Diabetes News and Diabetes Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...